Al-Reesi Abdullah, Al-Zadjali Nabil, Perry Jeff, Fergusson Dean, Al-Shamsi Mohammed, Al-Thagafi Majid, Stiell Ian
Deparment of Emergency Medicine, University of Ottawa, Ottawa, Ontario, Canada.
CJEM. 2008 May;10(3):215-23. doi: 10.1017/s1481803500010137.
Acute myocardial infarction (AMI) remains a major cause of death and beta-blockers are known to reduce long-term mortality in post-AMI patients. We sought to determine whether patients receiving beta-blockers acutely (within 72 h) following AMI had a lower mortality rate at 6 weeks than patients receiving placebo.
We conducted a systematic review of randomized controlled clinical trials that assessed 6-week mortality and compared beta-blockers with placebo in patients randomized within the first 72 hours following AMI. We searched these databases: MEDLINE (1966-2006), EMBASE (1980-2007), Cochrane Central Register of Controlled Trials, Health Star (1966-2007), Cochrane Database for Systematic Reviews, ACP Journal Club (1991-2007), Database of Abstracts of Reviews of Effect (< 1st quarter 2007) and Conference Papers Index (1984-2007). Two blinded reviewers extracted the data and rated study quality using the Jadad score and the adequacy of allocation concealment score, which was adopted by the Cochrane group. We calculated pooled odds ratios (ORs) using a random effect model and performed sensitivity analyses to explore the stability of the overall treatment effect.
We included 18 studies (13 were rated high-quality) with 74 643 enrolled participants and had 5095 deaths. Compared with placebo, adding beta-blockers to other interventions within 72 hours after AMI did not result in a statistically significant reduction in 6-week mortality (OR 0.95, 95% confidence interval [CI] 0.90-1.01). When restricted to high quality studies, the OR for 6-week mortality reduction was 0.96 (95% CI 0.91-1.02). We found similar results including studies that enrolled patients within 24 hours after AMI. However, a subgroup analysis that excluded high-risk patients with Killip class III and above showed that beta-blockers resulted in a significant reduction in short-term mortality (OR 0.93, 95% CI 0.88-0.99).
Acute intervention with beta-blockers does not result in a statistically significant short-term survival benefit following AMI but may be beneficial for low-risk (Killip class I) patients.
急性心肌梗死(AMI)仍然是主要的死亡原因,已知β受体阻滞剂可降低AMI后患者的长期死亡率。我们试图确定AMI后72小时内接受β受体阻滞剂急性治疗的患者在6周时的死亡率是否低于接受安慰剂的患者。
我们对随机对照临床试验进行了系统评价,这些试验评估了6周死亡率,并比较了AMI后72小时内随机分组的患者中β受体阻滞剂与安慰剂的效果。我们检索了以下数据库:MEDLINE(1966 - 2006年)、EMBASE(1980 - 2007年)、Cochrane对照试验中心注册库、Health Star(1966 - 2007年)、Cochrane系统评价数据库、ACP Journal Club(1991 - 2007年)、疗效评价文摘数据库(2007年第一季度之前)和会议论文索引(1984 - 2007年)。两名盲法评审员提取数据,并使用Cochrane小组采用的Jadad评分和分配隐藏充分性评分对研究质量进行评级。我们使用随机效应模型计算合并比值比(OR),并进行敏感性分析以探讨总体治疗效果的稳定性。
我们纳入了18项研究(13项被评为高质量),共有74643名受试者,其中5095人死亡。与安慰剂相比,AMI后72小时内在其他干预措施基础上加用β受体阻滞剂并未使6周死亡率有统计学意义的降低(OR 0.95,95%置信区间[CI] 0.90 - 1.01)。当仅限于高质量研究时,6周死亡率降低的OR为0.96(95% CI 0.91 - 1.02)。我们在纳入AMI后24小时内患者的研究中发现了类似结果。然而,一项排除Killip III级及以上高危患者的亚组分析显示,β受体阻滞剂可使短期死亡率显著降低(OR 0.93,95% CI 0.88 - 0.99)。
AMI后β受体阻滞剂的急性干预在短期生存获益方面无统计学意义,但可能对低风险(Killip I级)患者有益。